Skip to main content

Peer Review reports

From: Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial

Original Submission
18 Mar 2016 Submitted Original manuscript
Author responded Author comments
Reviewed Reviewer Report
Resubmission - Version 2
Submitted Manuscript version 2
Author responded Author comments
Resubmission - Version 3
Submitted Manuscript version 3
Publishing
21 Jul 2016 Editorially accepted
2 Aug 2016 Article published 10.1186/s12876-016-0494-4

You can find further information about peer review here.

Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us